TSC1 mRNA processing alterations in tuberous sclerosis complex (TSC) patients with negative or inconclusive genetic testing results

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by Fundo de Incentivo a Pesquisa e Eventos (FIPE) of Hospital de Clinicas de Porto Alegre, grant number 2015-0049. Patricia Ashton-Prolla is a researcher of CNPq (category 1B, process 313806-2021-7). Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)(Edital Fapergs number 09-2023) for Financial support.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Research Ethics Committee of Hospital de Clinicas de Porto Alegre under the protocol number 44739715.7.0000.5327 (Plataforma Brasil).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes